Microfluidic Devices: A New Paradigm in Toxicity Studies
Abstract
In recent years, great emphasis has been placed on non-animal toxicological methods (e.g.in vitro models,in silico or −omics data) as alternative strategies to reduce animal-testing, in line with the 3R principle. These methods help in the rapid and accurate estimation of preclinical efficacy and safety associated with discovery of new drugs, and reduction of failure rates in clinical trials. Currently, the in vitro studies have been in a transformation or replacement from two-dimensional cell cultures to three-dimensional cell cultures that can mimic the physiology of tissues, organs, and organism.
In this context, organ-on-a-chip systems have been developed by integration of three-dimensional culture models with emerging microfluidic technologies. The organ-on-a-chip systems provide a good understanding of dose-response and toxicity mechanisms in drug development process, since impact of xenobiotics on human body can be predicted in a satisfactory level. Besides, these systems may support assessment of pharmacokinetic-pharmacodynamic parameters as well as detection of drug resistance. Models can be generated as “disease-models-on-a-chip” or with healthy cells to evaluate response to xenobiotic under test.
In this study, we will focus on microfluidic systems being used in organ-on-a-chip systems and emphasize their potential for toxicity studies in which micro-environments of examples including liver,kidney,brain,lung,heart,and intestines and their physiological properties as reflected to organ-on-a-chip models.
Keywords
References
- [1] S.N. Bhatia, D.E. Ingber, Microfluidic organs-on-chips, Nat. Biotechnol. 32 (2014) 760–772.
- [2] M.B. Esch, A.S.T. Smith, J.-M. Prot, C. Oleaga, J.J. Hickman, M.L. Shuler, How multi-organ microdevices can help foster drug development, Adv. Drug Deliv. Rev. 69–70 (2014) 158–169.
- [3] C.M. Sakolish, M.B. Esch, J.J. Hickman, M.L. Shuler, G.J. Mahler, Modeling barrier tissues in vitro: Methods, Achievements, and Challenges, EBioMedicine. 5(2016) 30–39.
- [4] J.D. Caplin, N.G. Granados, M.R. James, R. Montazami, N. Hashemi, Microfluidic organ-on-a-chip technology for advancement of drug development and toxicology, Adv. Healthc. Mater. 4 (2015) 1426–1450.
- [5] R. Greek, A. Menache, Systematic Reviews of animal models: Methodology versus epistemology, Int. J. Med. Sci. 10 (2013) 206–221.
- [6] A. Skardal, T. Shupe, A. Atala, Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling, Drug Discov. Today. 21 (2016) 1399–1411.
- [7] L. Ewart, K. Fabre, A. Chakilam, Y. Dragan, D.B. Duignan, J. Eswaraka, J. Gan, P. Guzzie-Peck, M. Otieno, C.G. Jeong, D.A. Keller, S.M. de Morais, J.A. Phillips, W. Proctor, R. Sura, T. Van Vleet, D. Watson, Y. Will, D. Tagle, B. Berridge, Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective, Exp. Biol. Med. 242 (2017) 1579–1585.
- [8] S. Ishida, Organs-on-a-chip: Current applications and consideration points for in vitro ADME-Tox studies, Drug Metab. Pharmacokinet. 33 (2018) 49–54.
Details
Primary Language
English
Subjects
Engineering
Journal Section
Review
Authors
Kutay İçöz
0000-0002-0947-6166
Türkiye
Fatma Esra Yiğit
This is me
0000-0002-7512-3246
Türkiye
Publication Date
June 15, 2020
Submission Date
August 25, 2019
Acceptance Date
May 5, 2020
Published in Issue
Year 2020 Volume: 48 Number: 3